Magazine
#13 Abbott Laboratories
100 Abbott Park Rd., Abbott Park, IL 60064
Tel: (847) 937-6100Fax: (847) 937-9555
www.abbott.com
| Headcount (total) | 69,000 | |
| Year Established | 1888 | |
| Pharma Revenues | $16,013 | +9% |
| Total Revenues | $29,528 | +14% |
| Net Income | $4,881 | +35% |
| R&D Budget | $2,255 | -10% |
* 2006 revenues did not include TAP Pharmaceutical Products income
| 2008 Top Selling Drugs | |||
| Drug | Indication | Sales | (+/-%) |
| Humira | rheumatoid arthritis | $4,521 | +48% |
| Kaletra | HIV/AIDS | $1,474 | +11% |
| Depakote | bipolar disorder | $1,364 | -13% |
| TriCor | cholesterol | $1,341 | +10% |
| Ultane/Sevorane | anesthetic | $787 | +4% |
| Niaspan | cholesterol | $786 | +19% |
| Lupron | prostate cancer | $651 | n/a |
| Biaxin | antibiotic | $651 | -10% |
| Synthroid | hyperthyroidism | $524 | -2% |
Account for 76% of total pharma sales, up from 67% in 2007.
PROFILE
|
The Lowe Down
Abbott’s a sort of cousin to Johnson & Johnson compared to the other companies on this list. Its diagnostics and medical device wings give the business a different rhythm than that of pure pharma companies, and looking around the industry, Abbott’s probably fine with that. The drug department, though, is not immune to all the wonderful high-G-force maneuvers that the competition gets to experience. People are taking aim at their franchises in HIV and CNS, but they at least don’t have any of those monster patent expirations hanging over them (for now). And they’re making a big push in cardiovascular disease, with a number of drug combinations and the acquisition of Kos. All this ties into their devices business as well, since they’re doing very good business in the vicious stent market. Looking at them and at J&J, you have to think that the diverse-medical-products model has something going for it, at least in times like these. (When things are booming in the drug business, those other divisions look like so much ballast to be dealt with, naturally.) But since ‘times like these’ look to continue for a while, Abbott should, in theory, be in good shape to deal with them.—Derek Lowe |
The biggest news around Abbott is that it was allegedly the mystery company that was negotiating with Wyeth about a merger a few weeks before that deal with Pfizer came together. I have no idea whether that’s true, but I’m sure there would’ve been regulatory hangups over Humira and Enbrel (partly) belonging to the same company.
The company got cholesterol treatment Trilipix approved in December, and is partnering with AstraZeneca to get a combo of Trilipix and Crestor on the market. Abbott’s Trilipix/Tricor combo posted $253 million in 1Q09 sales.
Depakote notwithstanding, Abbott’s pharma business is in pretty good patent position, and once the companies ahead of it get swallowed up, it’ll be one of our top 10.
For the full Abbott profile, including pipeline and patent information, download the PDF.
Return to Top Pharma Report homepage.
